Xiao Zhang is 32 years old and has been a “major triple-positive” carrier since he was a child. The company’s father died of hepatitis B cirrhosis, Zhang’s uncle died of hepatitis B-associated liver cancer, and Zhang’s brother is also a hepatitis B carrier, so Zhang’s family can be considered the “hardest hit” by hepatitis B infection. The company’s main business is the development of a new product, which is a new product for the company. After taking lamivudine, Zhang stopped taking it after one year. In 2013, Zhang was referred to me for treatment, and by then, Zhang’s GTA was slowly rising, his ultrasound was normal, his liver hardness value was 8.4, and his blood count was normal. I suggested Xiao Zhang to review his liver function every three months or so, and consider antiviral treatment when the following three conditions are met: glutamate transaminase is more than twice the reference high value (usually more than 80); three consecutive months; and carefully exclude non-hepatitis B factors causing elevated transaminase such as fatty liver, drugs, alcohol, autoimmune, other viral infections, etc. After completing the relevant tests, I recommended that he start long-acting interferon injections (135 micrograms once a week). Xiao Zhang’s test results at the end of six months of treatment with Pyroxin were very unsatisfactory. The viral load was still as high as seven copies, the S antigen had dropped from more than 60,000 initially to about 20,000, and the concentration of E antigen was also high at more than 1,300. Glutathione transaminase gradually decreased from the initial 200+ to about 70. I advised Xiao Zhang to decisively discontinue Peroxin and immediately start oral entecavir combined with adefovir treatment. The purpose of the combination therapy was to consider that Xiao Zhang had a previous experience of lamivudine resistance. After the combination therapy, Xiao Zhang achieved very good results: three weeks later, the re-checked glutamate transaminase increased to about 400, and the viral load decreased to five copies. Considering that Xiao Zhang felt good about himself, I suggested him to continue to take entecavir combined with adefovir treatment, pay attention to rest, and do not use liver protection and enzyme-lowering drugs for the time being. After another half month, Xiao Zhang’s recheck results showed that the viral load had dropped to three copies, and the glutamate transaminase continued to rise to about 800. Zhang asked me, “Dr. Wang, in just five weeks, my viral load has dropped 10,000 times, which is a miracle! But how come the glutathione transaminase is rising higher and higher?” I told Zhang, “Your previous six months of Peroxyn did not go to waste, and laid the foundation for you to activate your own immune response to clear the hepatitis B virus afterwards. The rapid drop in viral load will further activate your own immune response to clear the hepatitis B virus, which will cause liver cell damage while the virus is cleared in large quantities and rapidly, so your GTA will rise higher and higher. With the rapid decline in the amount of virus, the glutathione aminotransferase will certainly gradually decline after a certain peak, do not need to worry too much,” I advised Zhang to pay more attention to rest, if the phenomenon of yellow eyes, urine yellow timely to the hospital for review, while taking Tianqing Ganping capsules. Half a month later, Zhang came to the hospital as scheduled for a review: the viral load was already below the lower limit of detection, and the glutamate transaminase dropped to about 200, and the E antigen dropped rapidly to about 200. After six months of treatment with entecavir combined with adefovir, Zhang’s hepatitis B surface antigen dropped from about 20,000 at the beginning of the course to 56 IU/ml (Abbott reagent), and his liver function was completely normalized. When Xiao Zhang completed one year of treatment with entecavir and adefovir, the results of the review were as follows: HBVDNA was less than 100 copies, hepatitis B surface antigen quantification was already very low, only 5.812, and E antigen quantification was also very low, 14.371, and liver function was completely normal. I happily said to Xiao Zhang: the treatment effect is very good, the quantification of hepatitis B surface antigen is already very low, and there is a hope to achieve the goal of clinical cure of hepatitis B in five years, and the hepatitis B surface antigen turns negative. Xiao Zhang’s treatment is very successful, summarizing his treatment experience, what inspiration can we get? First, the treatment of hepatitis B must choose the right time for treatment, and it is important to start the right treatment at the right time; second, we must try to stimulate the patient’s own immune response to clear the hepatitis B virus, the external cause must work through the internal cause, and the patient’s own immune response to clear the hepatitis B virus is the basis for the efficacy of the drug. If there is no contraindication to interferon, try to try interferon treatment first; third, to choose strong, non-resistant antiviral drugs, so that the combination of internal and external, the efficacy will naturally be very good.